JASPER, a phase II trial investigating pembrolizumab with niraparib as the first-line treatment in advanced NSCLC patients without EGFR mutations and ROS1/ALK translocations, showed that the ORR was 56.3% versus 20% in tumors with PD-L1 tumor proportion score (TPS) ≥ 50% and TPS < 50%, respectively, with similar side effects in those two groups [88]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.